Active	Status	Sponsor type	Region	Phase	Filter
4 Active 6 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
ATL1102 / Percheron Therapeutics, Ionis
ACTRN12618000970246: A safety and efficacy study of ATL1102 in patients with Duchenne Muscular Dystrophy	Recruiting	2	9	Rest Of World	ATL1102 - Antisense Therap, Ionis	Antisense Therapeutics Limited	Duchenne Muscular Dystrophy
2022-003065-38: A study of ATL1102 in participants with Duchenne Muscular Dystrophy (DMD) who cannot walk independently and require wheelchair assistance	Not yet recruiting	2	45	Europe	ATL1102, Solution for injection	Antisense Therapeutics Limited, Antisense Therapeutics Limited	Duchenne Muscular Dystrophy, Duchenne Muscular Dystrophy, Diseases [C] - Musculoskeletal Diseases [C05]
NCT05938023: A Study of ATL1102 or Placebo in Participants with Non-ambulatory Duchenne Muscular Dystrophy	Terminated	2	48	Europe, RoW	ATL1102 25mg, ATL1102 50mg, Placebo	Percheron Therapeutics	Duchenne Muscular Dystrophy	11/24	01/25
HMBD-002 / Percheron Therapeutics
NCT05082610: A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors	Active, not recruiting	1	313	US	HMBD-002, Pembrolizumab	Hummingbird Bioscience, Merck Sharp & Dohme LLC	Cancer, Tumor, Solid, Nonsmall Cell Lung Cancer, Triple Negative Breast Cancer, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor	11/24	07/25

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
ATL1102 / Percheron Therapeutics, Ionis
ACTRN12618000970246: A safety and efficacy study of ATL1102 in patients with Duchenne Muscular Dystrophy	Recruiting	2	9	Rest Of World	ATL1102 - Antisense Therap, Ionis	Antisense Therapeutics Limited	Duchenne Muscular Dystrophy
2022-003065-38: A study of ATL1102 in participants with Duchenne Muscular Dystrophy (DMD) who cannot walk independently and require wheelchair assistance	Not yet recruiting	2	45	Europe	ATL1102, Solution for injection	Antisense Therapeutics Limited, Antisense Therapeutics Limited	Duchenne Muscular Dystrophy, Duchenne Muscular Dystrophy, Diseases [C] - Musculoskeletal Diseases [C05]
NCT05938023: A Study of ATL1102 or Placebo in Participants with Non-ambulatory Duchenne Muscular Dystrophy	Terminated	2	48	Europe, RoW	ATL1102 25mg, ATL1102 50mg, Placebo	Percheron Therapeutics	Duchenne Muscular Dystrophy	11/24	01/25
HMBD-002 / Percheron Therapeutics
NCT05082610: A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors	Active, not recruiting	1	313	US	HMBD-002, Pembrolizumab	Hummingbird Bioscience, Merck Sharp & Dohme LLC	Cancer, Tumor, Solid, Nonsmall Cell Lung Cancer, Triple Negative Breast Cancer, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor	11/24	07/25